IOP sensor successfully implanted in first patient

Article

Implandata Ophthalmic Products GmbH (Implandata) says it has successfully implanted its EyeMate intraocular pressure (IOP) sensor implant in a first patient in Europe undergoing keratoprosthesis surgery.

Implandata Ophthalmic Products GmbH (Implandata) says it has successfully implanted its EyeMate IOP sensor in a first patient in Europe undergoing keratoprosthesis surgery.

The implantation was performed by study principal investigator Prof. Thomas Neuhann, medical director
and founder of the Laser Eye Center Munich, within the sponsor-initiated ARGOS-KP01 study.

More in this issue: Visual function linked to preBCVA in AMD cataract patients

Implandata’s telemetrically powered EyeMate IOP sensor implant allows for non-invasive measurement and monitoring of IOP in keratoprosthesis patients.

In this first implantation, EyeMate was placed in the patient’s eye at the same time the patient underwent the keratoprosthesis implantation. The sensor allows the patient’s IOP to be measured at any chosen frequency, either continuously or on demand at specific times. Patients can perform the measurements themselves, under the conditions of everyday life.

“Elevated IOP is a main issue with keratoprosthesis patients. Approximately two-thirds of these patients already do have glaucoma preoperatively and management of secondary glaucoma remains a major challenge postoperatively,” Prof. Neuhann said. “It is a breakthrough to obtain IOP information any time, with ease and at a quality which otherwise would only be available by performing invasive IOP measurements.”

 

The EyeMate is not yet CE marked or FDA approved. In the ongoing ARGOS-KP01 pre-market study, Implandata is seeking to create clinical data to approach the CE conformity process for use of the EyeMate sensor in keratoprosthesis patients. The company also is currently conducting in parallel its ARGOS-02 study, in which the EyeMate is being tested in primary open-angle glaucoma patients undergoing cataract surgery. Implandata said it is planning to conduct additional clinical studies in Europe and North America to validate complementary product versions for broader glaucoma applications.

http://www.implandata.com/Implandata Ophthalmic Products GmbH is a privately held medical device company founded in 2010 and headquartered in Hannover, Germany and Wilmington, DE, USA. For more information, go to Implandata Ophthalmic Products GmbH.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.